The upgraded, artificial intelligence (AI)-enabled software for the Swoop® Portable MR Imaging System reportedly enhances the device’s signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences.
The Food and Drug Administration (FDA) has granted 510(k) clearance for upgraded brain imaging software utilized with the Swoop® Portable MR Imaging System (Hyperfine).
The software includes an increased signal-to-noise ratio for diffusion-weighted magnetic resonance imaging (MRI) sequences as well as 10 percent increases in the fields of view for T1, T2 and FLAIR sequences that facilitate enhanced imaging of pathology deep in the brain, according to Hyperfine.
“The latest Swoop software improves image quality with notable improvement of the DWI images. The improved image quality more clearly displays underlying brain structure, further accentuating diffusion positivity and potentially increasing confidence in image interpretation and clinical decision-making,” noted Edward Knopp, M.D., the senior medical director of Hyperfine.
Hyperfine noted this is the 11th FDA clearance for the Swoop Portable MR Imaging System following the initial FDA clearance for the device in 2020 and nine subsequent clearances for hardware and software improvements.
In a related study, researchers, presenting data at the recent International Stroke Conference in Dallas, found the Swoop Portable MR Imaging System may enable physicians to perform baseline post-op assessments of heart rate and blood pressure changes that may contribute to brain injury in stroke patients who undergo a thrombectomy.
“We believe these observations set the stage for using portable MRI in the dynamic environment of acute stroke intervention where patients are at high risk for ongoing injury,” noted study co-author Kevin Sheth, M.D., a professor of neurology and neurosurgery at the Yale School of Medicine.
(Editor’s note: For related articles, see “New MRI Study Examines Impact of Disparities with Childhood Adversity Exposure on Brain Development,” “What an MRI Study Reveals About Low Alcohol Use During Pregnancy and Fetal Brain Structure” and “Brain MRI Study Shows ‘Significant Abnormalities’ Up to Six Months After COVID-19.”)
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.